Clinical Trials – Talk Bio

Synbio International Inc. Expands Its Board of Directors and Strengthens Clinical Leadership

16 hours ago talkbio0Tagged AI-driven, board of directors, Chief Financial Officer, Clinical Trials, Desiree Cain, Diagnostics, Nick Vatakis, Physician Executives, Synbio International Inc.

Synbio International Inc.; board of directors; Nick Vatakis; Desiree Cain; Medical Director; Chief Financial Officer; clinical trial; AI-driven diagnostics

Elevara Raises $70M to Advance Novel Rheumatoid Arthritis Treatment Targeting Synovial Fibroblasts

2 days ago talkbio0Tagged CDK4/6 inhibitor, Chronic inflammatory disorder, Clinical Trials, Elevara Medicines, ELV001, Forbion, Partner in relationship, Pharma, Rheumatoid Arthritis, Series A financing, Sofinnova, synovial fibroblasts, Teijin

Elevara Medicines; Series A financing; rheumatoid arthritis; ELV001; CDK4/6 inhibitor; synovial fibroblasts; Teijin Pharma; clinical trial; chronic inflammatory diseases; Forbion; Sofinnova Partners

Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients

3 days ago talkbio0Tagged AI-designed drug, brain-penetrant, Clinical Trials, IAM1363, Iambic Therapeutics, Malignant Neoplasms, Protein-tyrosine kinase inhibitor, Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance)

Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor

Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends

4 days ago talkbio0Tagged Astellas, Autoimmune Chronic Hepatitis, Clinical Trials, Kezar Life Sciences, Rett Syndrome, setback, strategic alternatives, Taysha Gene Therapies, TSHA-102, United States Food and Drug Administration, Zetomipzomib

Kezar Life Sciences; FDA setback; strategic alternatives; zetomipzomib; autoimmune hepatitis; Taysha Gene Therapies; Astellas; Rett syndrome; TSHA-102; clinical trials

Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine

7 days ago talkbio0Tagged Biotechnology, Clinical Development, Clinical Trials, Connecticut biotech, Fund Raising, hair loss treatment, Oral cavity, Phase 3, Rogaine, Veradermics

Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development

Gene Therapy Delivers Long-Term Immune Protection in Children With Rare Immune Disorders

1 week ago talkbio0Tagged Adenosine deaminase deficiency, Clinical Trials, Combined immunodeficiency disease, Congenital leukocyte adherence deficiency, Curative Therapy, gene therapy, immune protection, Leukocyte adhesion deficiency type 1, Long-term, Pediatric immunology, Rare Diseases, Severe (severity modifier)

gene therapy; long-term immune protection; ADA-SCID; severe combined immunodeficiency; LAD-I; leukocyte adhesion deficiency; rare disease; pediatric immunology; clinical trial; curative treatment

Lilly’s Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

1 week ago talkbio0Tagged ACHIEVE-1, ATTAIN-2, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Effectiveness, Eli Lilly, Farxiga, Glucagon-Like Peptide 1, Oral cavity, orforglipron, regulatory submission, Safety, semaglutide, Weight Loss

Lilly; Orforglipron; oral GLP-1; type 2 diabetes; clinical trial; weight loss; regulatory submission; ACHIEVE-1; ATTAIN-2; semaglutide; Farxiga; efficacy; safety

Tubulis Secures $361 Million Series C to Advance Clinical-Stage Antibody-Drug Conjugates (ADCs)

1 week ago talkbio0Tagged Antibody-Drug Conjugates, cancer therapeutics, Clinical Trials, Optimization, precision oncology, Series C funding, Solid Neoplasm, therapeutic autologous dendritic cells, TUB-030, TUB-040, Tubulis

Tubulis; Series C funding; antibody-drug conjugates; ADC; precision oncology; cancer therapeutics; TUB-040; TUB-030; solid tumors; clinical trials; biotech; platform optimization

Spotlight On: Cabaletta Bio’s Small but Mighty Breakthrough for CAR-T in Autoimmune Arena

1 week ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, Cabaletta Bio, CAR-T therapy, Clinical Trials, Depletion, Lupus Erythematosus, Systemic, Myositis, Pemphigus Vulgaris, Preconditioning, rese-cel, Systemic Scleroderma, United States Food and Drug Administration

Cabaletta Bio; CAR-T therapy; rese-cel; autoimmune diseases; B cell depletion; myositis; systemic lupus erythematosus; systemic sclerosis; pemphigus vulgaris; preconditioning; clinical trial; FDA

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

2 weeks ago talkbio0Tagged adjuvant Tecentriq, Clinical Oncology, Clinical Trials, ESMO Congress, Molecular residual disease, muscle-invasive bladder cancer, Natera, Precision Medicine, Presidential Symposium, Signatera

Natera; ESMO Congress; IMvigor011 trial; Presidential Symposium; Signatera; molecular residual disease; muscle-invasive bladder cancer; adjuvant Tecentriq; precision medicine; clinical oncology